Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0071 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0071 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0071 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0071 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0071 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0071 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0071 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | Antiparasitic activity against axenic amastigote forms of Leishmania donovani MHOM/ET/67/L82 assessed as inhibition of growth after 72 hrs by resazurin assay | ChEMBL. | 25240098 | |
IC50 (functional) | = 32.2 uM | Antiparasitic activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells assessed as inhibition of growth after 96 hrs by inverted microscopy | ChEMBL. | 25240098 |
IC50 (functional) | = 39.4 uM | Antiparasitic activity against bloodstream forms of Trypanosoma brucei rhodesiense STIB 900 assessed as inhibition of growth after 72 hrs by resazurin assay | ChEMBL. | 25240098 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.